Arrowhead files for approval of dual-target RNAi therapy for heart disease
PositiveFinancial Markets

Arrowhead has taken a significant step by filing for approval of a dual-target RNA interference therapy aimed at treating heart disease. This innovative approach could potentially revolutionize how we manage this prevalent condition, offering new hope to millions affected by heart issues. The approval process will be closely watched, as it could pave the way for more advanced treatments in the future.
— Curated by the World Pulse Now AI Editorial System